Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...

A study published earlier this year in the Journal of Neuro-Oncology indicates that sonodynamic therapy (SDT) safely destroys GBM cells while preserving healthy brain tissue. Using a noninvasive ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the ...

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

A promising treatment option is on the horizon for some patients with glioblastoma multiforme (GBM), says Martin van den Bent, M.D., Ph.D. ABT-414, an antibody drug conjugate, showed promising results ...

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

A nano-sized medicine boosts the anti-cancer immune response and eradicates tumors in mice. Researchers at Washington University School of Medicine in St. Louis, working with colleagues at ...

Medical researchers have announced the results of an innovative treatment approach that may offer improvement in overall survival in older patients with newly diagnosed glioblastoma while maintaining ...

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...

The novel glioblastoma treatment, APTN-101, had its new drug application accepted by the FDA. The Food and Drug Administration (FDA) has cleared an investigational new drug application for the novel ...

HOUSTON, TX / ACCESSWIRE / October 16, 2023 / Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis. There is currently no cure for ...